

**RECORDATI: UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM**

Milan, 21 May 2013 – Within the Recordati's share buy-back program announced on 9 May 2013 with the object of purchasing Recordati ordinary shares for the servicing of current and future stock option plans in favour of certain group employees, the Company informs the following purchase transactions, pursuant to art. 87 bis of Consob Regulation 11971/1999 ("Issuers Regulations").

<b>SUMMARY OF TRANSACTIONS FROM 13 MAY 2013 TO 20 MAY 2013</b>					
<b>Date</b>	<b>Type of Transaction</b>	<b>Financial Instrument</b>	<b>Quantity</b>	<b>Average price</b>	<b>Consideration</b>
13.05.2013	Purchase	Ord. Shares Recordati	11,356.00	7.8905	89,605.08
14.05.2013	Purchase	Ord. Shares Recordati	18,455.00	8.0281	148,158.59
16.05.2013	Purchase	Ord. Shares Recordati	108,896.00	8.0727	879,083.27
17.05.2013	Purchase	Ord. Shares Recordati	95,000.00	8.0178	761,688.97
20.05.2013	Purchase	Ord. Shares Recordati	35,560.00	7.9609	283,088.27
<b>TOTAL</b>			<b>269,267.00</b>		<b>2,161,624.18</b>

On 20 May 2013, the Company has n. 7,737,557.00 own shares in Treasury stock which amounts to 3.69% of the current share capital.

*Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of over 3,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey and in the United States of America. A field force of more than 1,700 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2012 was € 828.3 million, operating income was € 167.0 million and net income was € 118.5 million.*

For further information:

Recordati website: [www.recordati.com](http://www.recordati.com)

Investor Relations

Marianne Tatschke  
(39)0248787393  
e-mail: [inver@recordati.it](mailto:inver@recordati.it)

Media Relations

Ketchum  
Cristina Risciotti, (39)0262411919, [cristina.risciotti@ketchum.com](mailto:cristina.risciotti@ketchum.com)  
Marzia Ongaretti, (39)0262411915, [marzia.ongaretti@ketchum.com](mailto:marzia.ongaretti@ketchum.com)

*Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions*  
**RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.**

Sede Legale  
VIA M. CIVITALI, 1  
20148 MILANO, ITALIA  
TEL. (39) 0248787.1  
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.  
REG. IMP. MILANO N. 00748210150  
CODICE FISCALE/P.IVA 007482210150  
R.E.A. MILANO N. 401832

*may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.*